{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:01:16Z","timestamp":1791860476001,"version":"4.3.4"},"reference-count":64,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: Chondrosarcoma is a rare bone malignancy with a poor response to systemic therapy in advanced stages. European-level epidemiological data remain scarce. This study aimed to characterise patient demographics, treatments and survival using real-world data to inform regulatory decisions about the feasibility and design of new trials for the systemic treatment of chondrosarcoma.\nPatient\/material and methods: This cohort study, part of the DARWIN EU\u00ae initiative, analysed data from six healthcare databases in Finland, France, the Netherlands, Spain and the UK. Patients diagnosed with chondrosarcoma between 2010 and 2022 were identified. Standardised analyses were performed within a federated network using the Observational Medical Outcomes Partnership (OMOP) Common Data Model.\nResults: A total of 2,498 chondrosarcoma patient records were identified, covering at least 2,356 unique patients. Median age at diagnosis was 52\u201355 years, with a balanced sex distribution. Surgical treatment was the most common intervention, recorded in 15.2% to 88.9% of patients, depending on the database. Fewer than 5% received systemic anticancer therapy, and radiotherapy was reported in fewer than 7%. The 10-year overall survival (OS) ranged from 58% (95% confidence interval [CI]: 43\u201378) to 80% (95% CI: 78\u201382), with restricted mean survival between 7.4 and 8.7 years. In the Netherlands, patients with late-stage, metastatic or high-grade disease showed significantly poorer outcomes.\nInterpretation: This study demonstrates the feasibility of using real-world data across Europe to describe chondrosarcoma patients. Most had early-stage, low-grade disease amenable to surgery, with limited use of systemic therapies. Survival was generally favourable, except in advanced disease. Clinical trials remain difficult due to the rarity of advanced chondrosarcoma and the lack of standards.<\/jats:p>","DOI":"10.2340\/1651-226x.2026.45117","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:53:28Z","timestamp":1773212008000},"page":"193-200","source":"Crossref","is-referenced-by-count":1,"title":["Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU\u00ae cohort study"],"prefix":"10.2340","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4629-3326","authenticated-orcid":false,"given":"Anton","family":"Barchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4453-3071","authenticated-orcid":false,"given":"Cesar","family":"Barboza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7315-034X","authenticated-orcid":false,"given":"Julieta","family":"Politi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4668-2970","authenticated-orcid":false,"given":"Berta","family":"Ravent\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0444-4579","authenticated-orcid":false,"given":"Peter","family":"Prinsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-9786","authenticated-orcid":false,"given":"Jelle","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-928X","authenticated-orcid":false,"given":"Vincent KY","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7656","authenticated-orcid":false,"given":"Michiel AJ","family":"Van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7847-7479","authenticated-orcid":false,"given":"Eric","family":"Fey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-5902","authenticated-orcid":false,"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hammais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3910-796X","authenticated-orcid":false,"given":"Tiina","family":"Wahlfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-2208","authenticated-orcid":false,"given":"Tuomo","family":"Nieminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2089-2299","authenticated-orcid":false,"given":"Toni","family":"Lehtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-3403","authenticated-orcid":false,"given":"Antonella","family":"Delmestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0745-0034","authenticated-orcid":false,"given":"Guillaume","family":"Verdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-137X","authenticated-orcid":false,"given":"Romain","family":"Griffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4928-0491","authenticated-orcid":false,"given":"Airam","family":"De Burgos-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Llorente-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Justo-Astorgano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1471-4376","authenticated-orcid":false,"given":"Miguel-Angel","family":"Macia-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0802-1619","authenticated-orcid":false,"given":"Olli","family":"Tenhunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-4731","authenticated-orcid":false,"given":"Anja","family":"Schiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2217-0540","authenticated-orcid":false,"given":"Alexandra","family":"Pacurariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-417X","authenticated-orcid":false,"given":"Ross","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-4904","authenticated-orcid":false,"given":"Katia","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8274-0357","authenticated-orcid":false,"given":"Talita","family":"Duarte Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"144176","doi-asserted-by":"crossref","unstructured":"Valery PC, Laversanne M, Bray F. Bone cancer incidence by morphological subtype: a global assessment. Cancer Causes Control. 2015;26(8):1127\u201339.","DOI":"10.1007\/s10552-015-0607-3"},{"key":"144177","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10552-015-0607-3","DOI":"10.1007\/s10552-015-0607-3"},{"key":"144178","doi-asserted-by":"crossref","unstructured":"Gelderblom H, Hogendoorn PCW, Dijkstra SD, Van Rijswijk CS, Krol AD, Taminiau AHM, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13(3):320\u20139.","DOI":"10.1634\/theoncologist.2007-0237"},{"key":"144179","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1634\/theoncologist.2007-0237","DOI":"10.1634\/theoncologist.2007-0237"},{"key":"144180","doi-asserted-by":"crossref","unstructured":"Thorkildsen J, Myklebust T\u00c5. The national incidence of chondrosarcoma of bone; a review. Acta Oncol. 2023;62(2):110\u20137.","DOI":"10.1080\/0284186X.2023.2177975"},{"key":"144181","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2023.2177975","DOI":"10.1080\/0284186X.2023.2177975"},{"key":"144182","doi-asserted-by":"crossref","unstructured":"Van Praag (Veroniek) VM, Rueten-Budde AJ, Ho V, Dijkstra PDS, Fiocco M, Van De Sande MAJ, et al. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. Surg Oncol. 2018;27(3):402\u20138.","DOI":"10.1016\/j.suronc.2018.05.009"},{"key":"144183","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.suronc.2018.05.009","DOI":"10.1016\/j.suronc.2018.05.009"},{"key":"144184","doi-asserted-by":"crossref","unstructured":"Suster D, Hung YP, Nielsen GP. Differential diagnosis of cartilaginous lesions of bone. Archiv Pathol Lab Med. 2020;144(1):71\u201382.","DOI":"10.5858\/arpa.2019-0441-RA"},{"key":"144185","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5858\/arpa.2019-0441-RA","DOI":"10.5858\/arpa.2019-0441-RA"},{"key":"144186","doi-asserted-by":"crossref","unstructured":"Choi JH, Ro JY. The 2020 WHO classification of tumors of bone: an updated review. Adv Anat Pathol. 2021;28(3):119\u201338.","DOI":"10.1097\/PAP.0000000000000293"},{"key":"144187","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/PAP.0000000000000293","DOI":"10.1097\/PAP.0000000000000293"},{"key":"144188","doi-asserted-by":"crossref","unstructured":"Thorkildsen J, Taksdal I, Bjerkehagen B, Haugland HK, B\u00f8rge Johannesen T, Viset T, et al. Chondrosarcoma in Norway 1990\u20132013; an epidemiological and prognostic observational study of a complete national cohort. Acta Oncol. 2019;58(3):273\u201382.","DOI":"10.1080\/0284186X.2018.1554260"},{"key":"144189","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2018.1554260","DOI":"10.1080\/0284186X.2018.1554260"},{"key":"144190","doi-asserted-by":"crossref","unstructured":"Polychronidou G, Karavasilis V, Pollack SM, Huang PH, Lee A, Jones RL. Novel therapeutic approaches in chondrosarcoma. Future Oncol. 2017;13(7):637\u201348.","DOI":"10.2217\/fon-2016-0226"},{"key":"144191","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/fon-2016-0226","DOI":"10.2217\/fon-2016-0226"},{"key":"144192","doi-asserted-by":"crossref","unstructured":"Ottesen TD, Shultz BN, Munger AM, Amick M, Toombs CS, Friedaender GE, et al. Chondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the National Cancer Database (NCDB). PLoS One. 2022;17(7):e0268215.","DOI":"10.1371\/journal.pone.0268215"},{"key":"144193","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0268215","DOI":"10.1371\/journal.pone.0268215"},{"key":"144194","doi-asserted-by":"crossref","unstructured":"Nota SPFT, Braun Y, Schwab JH, Van Dijk CN, Bramer JAM. The identification of prognostic factors and survival statistics of conventional central chondrosarcoma. Sarcoma. 2015;2015:1\u201311.","DOI":"10.1155\/2015\/623746"},{"key":"144195","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1155\/2015\/623746","DOI":"10.1155\/2015\/623746"},{"key":"144196","doi-asserted-by":"crossref","unstructured":"Dernie F, Corby G, Robinson A, Bezer J, Mercade\u2010Besora N, Griffier R, et al. Standardised and reproducible phenotyping using distributed analytics and tools in the Data Analysis and Real World Interrogation Network (DARWIN EU). Pharmacoepidemiol Drug. 2024;33(11):e70042.","DOI":"10.1002\/pds.70042"},{"key":"144197","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/pds.70042","DOI":"10.1002\/pds.70042"},{"key":"144198","doi-asserted-by":"crossref","unstructured":"Ravent\u00f3s B, Prieto-Alhambra D. Real-world evidence for regulatory purposes: the example of DARWIN EU\u00ae. Farm Hosp. 2025;49(2):62\u20134.","DOI":"10.1016\/j.farma.2025.02.011"},{"key":"144199","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.farma.2025.02.011","DOI":"10.1016\/j.farma.2025.02.011"},{"key":"144200","doi-asserted-by":"crossref","unstructured":"Leinonen MK, Miettinen J, Heikkinen S, Pitk\u00e4niemi J, Malila N. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;77:31\u20139.","DOI":"10.1016\/j.ejca.2017.02.017"},{"key":"144201","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.017","DOI":"10.1016\/j.ejca.2017.02.017"},{"key":"144202","doi-asserted-by":"crossref","unstructured":"Sanden GAC van D, Coebergh JWW, Schouten LJ, Visser O, Leeuwen FE van. Cancer incidence in the Netherlands in 1989 and 1990: first results of the nationwide Netherlands cancer registry. Eur J Cancer. 1995;31(11):1822\u20139.","DOI":"10.1016\/0959-8049(95)00355-M"},{"key":"144203","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0959-8049(95)00355-M","DOI":"10.1016\/0959-8049(95)00355-M"},{"key":"144204","doi-asserted-by":"crossref","unstructured":"Chaplin A, Archangelidi O, Hagberg K, Neasham D, Kafatos G. Comparison of epidemiological estimates for 19 cancer types using electronic health record databases in England: an analysis of CPRD aurum and CPRD GOLD Databases with linked hospital episode statistics and cancer registry data. CLEP. 2025;17:1025\u201338.","DOI":"10.2147\/CLEP.S558429"},{"key":"144205","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S558429","DOI":"10.2147\/CLEP.S558429"},{"key":"144206","doi-asserted-by":"crossref","unstructured":"Blacketer C, Defalco FJ, Ryan PB, Rijnbeek PR. Increasing trust in real-world evidence through evaluation of observational data quality. J Am Med Inform Assoc. 2021;28(10):2251\u20137.","DOI":"10.1093\/jamia\/ocab132"},{"key":"144207","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jamia\/ocab132","DOI":"10.1093\/jamia\/ocab132"},{"key":"144208","doi-asserted-by":"crossref","unstructured":"Reich C, Ostropolets A, Ryan P, Rijnbeek P, Schuemie M, Davydov A, et al. OHDSI Standardized vocabularies \u2013 a large-scale centralized reference ontology for international data harmonization. J Am Med Inform Assoc. 2024;31(3):583\u201390.","DOI":"10.1093\/jamia\/ocad247"},{"key":"144209","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jamia\/ocad247","DOI":"10.1093\/jamia\/ocad247"},{"key":"144210","doi-asserted-by":"crossref","unstructured":"Hripcsak G, Albers DJ. High-fidelity phenotyping: richness and freedom from bias. J Am Medi Inform Assoc. 2018;25(3):289\u201394.","DOI":"10.1093\/jamia\/ocx110"},{"key":"144211","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jamia\/ocx110","DOI":"10.1093\/jamia\/ocx110"},{"key":"144212","unstructured":"Catala M, Guo Y, Du M, Lopez-Guell K, Burn E, Mercade-Besora N, et al. PatientProfiles: identify characteristics of patients in the OMOP common data model. 2025 [cited 2025 Apr 08]. Available from: https:\/\/cran.r-project.org\/web\/packages\/PatientProfiles\/index.html"},{"key":"144213","unstructured":"L\u00f3pez-G\u00fcell K, Burn E, Catala M, Li X, Newby D, Mercade-Besora N. CohortSurvival: estimate survival from common data model cohorts. 2025 [cited 2025 Apr 08]. Available from: https:\/\/cran.r-project.org\/web\/packages\/CohortSurvival\/index.html"},{"key":"144214","doi-asserted-by":"crossref","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220\u20137.","DOI":"10.1158\/1078-0432.CCR-08-2740"},{"key":"144215","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2740","DOI":"10.1158\/1078-0432.CCR-08-2740"},{"key":"144216","doi-asserted-by":"crossref","unstructured":"Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, et al. SARC009: phase 2 study of dasatinib in patients with previously treated, high\u2010grade, advanced sarcoma. Cancer. 2016;122(6):868\u201374.","DOI":"10.1002\/cncr.29858"},{"key":"144217","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.29858","DOI":"10.1002\/cncr.29858"},{"key":"144218","doi-asserted-by":"crossref","unstructured":"Rock A, Ali S, Chow WA. Systemic therapy for chondrosarcoma. Curr Treat Options Oncol. 2022;23(2):199\u2013209.","DOI":"10.1007\/s11864-022-00951-7"},{"key":"144219","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11864-022-00951-7","DOI":"10.1007\/s11864-022-00951-7"},{"key":"144220","doi-asserted-by":"crossref","unstructured":"Duffaud F, Italiano A, Bompas E, Rios M, Penel N, Mir O, et al. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. Eur J Cancer. 2021;150:108\u201318.","DOI":"10.1016\/j.ejca.2021.03.039"},{"key":"144221","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2021.03.039","DOI":"10.1016\/j.ejca.2021.03.039"},{"key":"144222","doi-asserted-by":"crossref","unstructured":"Wagner MJ, Ricciotti RW, Mantilla J, Loggers ET, Pollack SM, Cranmer LD. Response to PD1 inhibition in conventional chondrosarcoma. J Immunother Cancer. 2018;6(1):94.","DOI":"10.1186\/s40425-018-0413-z"},{"key":"144223","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s40425-018-0413-z","DOI":"10.1186\/s40425-018-0413-z"},{"key":"144224","doi-asserted-by":"crossref","unstructured":"Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Solis Soto L, et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022;23(9):1156\u201366.","DOI":"10.1016\/S1470-2045(22)00392-8"},{"key":"144225","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(22)00392-8","DOI":"10.1016\/S1470-2045(22)00392-8"},{"key":"144226","doi-asserted-by":"crossref","unstructured":"Trama A, Bernasconi A, Ca\u00f1ete A, Carulla M, Daubisse-Marliac L, Rossi S, et al. Incidence and survival of rare adult solid cancers in Europe (EUROCARE-6): a population-based study. Eur J Cancer. 2025;214:115147.","DOI":"10.1016\/j.ejca.2024.115147"},{"key":"144227","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115147","DOI":"10.1016\/j.ejca.2024.115147"},{"key":"144228","doi-asserted-by":"crossref","unstructured":"Trama A, Lasalvia P, Stark D, McCabe MG, Van Der Graaf W, Gaspar N, et al. Incidence and survival of European adolescents and young adults diagnosed with sarcomas: EUROCARE-6 results. Eur J Cancer. 2025;217:115212.","DOI":"10.1016\/j.ejca.2024.115212"},{"key":"144229","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115212","DOI":"10.1016\/j.ejca.2024.115212"},{"key":"144230","doi-asserted-by":"crossref","unstructured":"Kondo H, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, et al. Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry. Jpn J Clin Oncol. 2025:5(5):490\u20137.","DOI":"10.1093\/jjco\/hyaf024"},{"key":"144231","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jjco\/hyaf024","DOI":"10.1093\/jjco\/hyaf024"},{"key":"144232","doi-asserted-by":"crossref","unstructured":"Nie Z, Lu Q, Peng H. Prognostic factors for patients with chondrosarcoma: a survival analysis based on the Surveillance, Epidemiology, and End Results (SEER) database (1973\u20132012). J Bone Oncol. 2018;13:55\u201361.","DOI":"10.1016\/j.jbo.2018.09.003"},{"key":"144233","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jbo.2018.09.003","DOI":"10.1016\/j.jbo.2018.09.003"},{"key":"144234","unstructured":"Miyazaki T, Oike N, Ariizumi T, Murayama Y, Hatano H, Yamagishi T, et al. A retrospective study of post-radiation sarcoma from three institutions in Japan with a review of the literature. Nagoya J Med Sci. 2025;87(4):747\u201365."},{"key":"144235","unstructured":"https:\/\/doi.org\/10.18999\/nagjms.87.4.747"},{"key":"144236","doi-asserted-by":"crossref","unstructured":"Peretz Soroka H, Vora T, Noujaim J, Marcoux N, Cohen\u2010Gogo S, Alcindor T, et al. Real\u2010world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: a Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study. Cancer Med. 2023;12(18):18872\u201381.","DOI":"10.1002\/cam4.6515"},{"key":"144237","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cam4.6515","DOI":"10.1002\/cam4.6515"},{"key":"144238","doi-asserted-by":"crossref","unstructured":"Tap WD, Cote GM, Burris H, Gore L, Elias A, Beeram M, et al. Phase I study of the mutant IDH1 inhibitor ivosidenib: long-term safety and clinical activity in patients with conventional chondrosarcoma. Clin Cancer Res. 2025;31(11):2108\u201314.","DOI":"10.1158\/1078-0432.CCR-24-4128"},{"key":"144239","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-4128","DOI":"10.1158\/1078-0432.CCR-24-4128"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45117\/53115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/45117\/53115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:53:35Z","timestamp":1773212015000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/45117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":64,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2026.45117","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}